ReviewCNS neuroscience & therapeutics2011
Seeking brain biomarkers for preventive therapy in Huntington disease.
Review in CNS neuroscience & therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Glymphatic influx and clearance are perturbed in Huntington's disease.JCI insight · 2024Article
- Working Memory-Related Effective Connectivity in Huntington's Disease Patients.Frontiers in neurology · 2018Article
- Major Superficial White Matter Abnormalities in Huntington's Disease.Frontiers in neuroscience · 2016Article
- Prefrontal cortex white matter tracts in prodromal Huntington disease.Human brain mapping · 2015Article
- The relationship between atrophy and hypometabolism: is it regionally dependent in dementias?Current neurology and neuroscience reports · 2015Review
- Functional magnetic resonance imaging of working memory in Huntington's disease: cross-sectional data from the IMAGE-HD study.Human brain mapping · 2014Article
- Prospects for neuroprotective therapies in prodromal Huntington's disease.Movement disorders : official journal of the Movement Disorder Society · 2014Review
- Deep white matter in Huntington's disease.PloS one · 2014Article
- The evolving role of diffusion magnetic resonance imaging in movement disorders.Current neurology and neuroscience reports · 2013Review
- Tractography of the corpus callosum in Huntington's disease.PloS one · 2013Article
- Decreased Metabolism in the Cerebral Cortex in Early-Stage Huntington's Disease: A Possible Biomarker of Disease Progression?Journal of clinical neurology (Seoul, Korea) · 2013Article
- Monitoring Huntington's disease progression through preclinical and early stages.Neurodegenerative disease management · 2012Article
- 18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size.European journal of nuclear medicine and molecular imaging · 2012Article
- Brain networks in Huntington disease.The Journal of clinical investigation · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huntington disease (HD) is a severe incurable nervous system disease that generally has an onset age of around 35-50, and is caused by a dominantly transmitted expansion mutation. A genetic test allows persons at risk, i.e., offspring or siblings of affected individuals, to discover their genetic status. Unaffected mutation-positive subjects will manifest HD sometime during life. Despite major advances in research on pathogenic mechanisms, no studies have yet fully validated preventive therapy or biomarkers for use before the symptoms become clinically manifest. Seeking brain and peripheral biomarkers is a requisite to develop a cure for HD. Changes in the brain can be observed in vivo using methods such as structural magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), functional MRI (fMRI), and positron emission tomography (PET), detecting volumetric changes, microstructural and connectivity alterations, abnormalities in brain activity in response to specific tasks, and abnormalities in metabolism and receptor distribution. Although all these imaging techniques can detect early markers in asymptomatic HD gene carriers for premanifest screening and pharmacological responses to therapeutic interventions no single modality has yet provided and validated an optimal marker probably because this task requires an integrative multimodal imaging approach. In this article, we review the findings from imaging procedures in the attempt to identify potential brain markers, so-called dry biomarkers, for possible application to further, yet unavailable, neuroprotective preventive therapies for HD manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.